AUTH/2544/11/12: GP v Napp — BuTrans promotional emails to NHS address (no breach)

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2544/11/12
ComplainantGeneral practitioner
CompanyNapp Pharmaceuticals Limited
ProductBuTrans (buprenorphine matrix patch)
IssuePromotional emails sent to an NHS email address; question over how the address was used and whether prior permission existed
ChannelEmail promotion via a third-party agency/resource
Applicable Code year2011
Clauses consideredClauses 9.1 and 9.9
Panel decisionNo breach of Clause 9.9; consequently no breach of Clause 9.1
AppealNo appeal
Complaint received6 August 2012
Case completed15 October 2012

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A general practitioner complained that she received a BuTrans (buprenorphine matrix patch) advertisement twice to her NHS email address.
  • She said she generally avoided pharma representatives due to concerns about influencing prescribing decisions, and queried how her NHS email address was used for promotion.
  • Napp said a third-party agency sent the digital advertisement on its behalf and that the GP had previously opted in to receive such emails via the agency’s registration process.
  • The promotional email included information on how to unsubscribe.
  • The Panel considered the email to be promotional and noted companies remain responsible for third parties acting on their behalf.
⚖️

Outcome

  • No breach of Clause 9.9 (email promotion requires prior permission) because there was evidence the GP had agreed to receive promotional material by email via the agency’s opt-in process.
  • No breach of Clause 9.1 (high standards) as a consequence.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training